[Clinical Trial News] DESTINY-Breast04 in ASCO 2022OOTRJun 20, 20221 min readFam-Trastuzumab Deruxtecan-nxki Doubles Progression-Free Survival in HER2-Low Metastatic Breast CancerClick the link below to read more: https://ascopost.com/news/june-2022/fam-trastuzumab-deruxtecan-nxki-doubles-progression-free-survival-in-her2-low-metastatic-breast-cancer/
[Clinical Trial News] DESTINY-Breast03 in ASCO 2022DESTINY-Breast03: Should Trastuzumab Deruxtecan Be the Preferred Second-Line Regimen in HER2-Positive Metastatic Breast Cancer? Click the...
Comments